Home > Compound List > Product Information
Flurazepam_Molecular_structure_CAS_17617-23-1)
Click picture or here to close

Flurazepam

Catalog No. DB00690 Name DrugBank
CAS Number 17617-23-1 Website http://www.ualberta.ca/
M. F. C21H23ClFN3O Telephone (780) 492-3111
M. W. 387.8782232 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 572

SYNONYMS

IUPAC name
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
IUPAC Traditional name
flurazepam
Brand Name
Noctosom
Dalmane
Valdorm
Somnol
Felison
Felmane
Flunox
Insumin
Paxane
Stauroderm
Dalmadorm
Synonyms
Flurazepam HCL

DATABASE IDS

PubChem CID 3393
CAS Number 17617-23-1
PubChem SID 46508451

PROPERTIES

Hydrophobicity(logP) 3.8
Solubility 500 mg/mL (HCl salt)

DETAILS

Description (English)
Item Information
Drug Groups illicit; approved
Description A benzodiazepine derivative used mainly as a hypnotic. [PubChem]
Indication For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
Pharmacology Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.
Toxicity Coma, confusion, low blood pressure, sleepiness
Affected Organisms
Humans and other mammals
Biotransformation Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form
Absorption Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
Half Life The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
Protein Binding 83%
Elimination Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.
References
[Link]
Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [Pubmed]
Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [Pubmed]
Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed]
Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [Pubmed]
Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES

  • Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. Pubmed
  • Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. Pubmed
  • Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed
  • Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. Pubmed
  • Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. Pubmed
  • Link